Characteristics of patients for surgical approach, before and after inverse probability of treatment weighting
| Characteristic | Cohort before inverse probability of treatment weighting | Cohort after inverse probability of treatment weighting** | ||||
| Laparotomy (n=697) | Laparoscopy (n=688) | P-value | Laparotomy (n=698) | Laparoscopy (n=681) | P-value* | |
| Age | < 0.001 | 0.949 | ||||
| 22–39 | 145 (20.8%) | 230 (33.4%) | 188 (26.9%) | 187 (27.5%) | ||
| 40–49 | 190 (27.3%) | 230 (33.4%) | 214 (30.6%) | 211 (31.0%) | ||
| 50–59 | 198 (28.4%) | 168 (24.4%) | 185 (26.6%) | 183 (26.8%) | ||
| >=60 | 164 (23.5%) | 60 (8.7%) | 111 (15.9%) | 100 (14.7%) | ||
| FIGO stage | 0.244 | 0.926 | ||||
| IA1 | 15 (2.2%) | 9 (1.3%) | 12 (1.7%) | 10 (1.5%) | ||
| IA2 | 35 (5.0%) | 45 (6.5%) | 42 (6.0%) | 40 (5.9%) | ||
| IB1 | 647 (92.8%) | 634 (92.2%) | 644 (92.3%) | 631 (92.6%) | ||
| Histology | 0.373 | 0.926 | ||||
| Adenocarcinoma | 196 (28.1%) | 214 (31.1%) | 208 (29.8%) | 206 (30.3%) | ||
| Adenosquamous | 34 (4.9%) | 27 (3.9%) | 28 (4.0%) | 24 (3.6%) | ||
| Squamous | 467 (67.0%) | 447 (65.0%) | 462 (66.3%) | 451 (66.2%) | ||
| Histological grade | < 0.001 | 0.983 | ||||
| Grade 1 | 71 (10.2%) | 141 (20.5%) | 104 (15.0%) | 106 (15.6%) | ||
| Grade 2 | 437 (62.7%) | 388 (56.4%) | 420 (60.2%) | 409 (60.0%) | ||
| Grade 3 | 104 (14.9%) | 102 (14.8%) | 104 (14.9%) | 102 (15.0%) | ||
| Missing | 85 (12.2%) | 57 (8.3%) | 69 (10.0%) | 65 (9.5%) | ||
| Tumor size | 0.651 | 0.925 | ||||
| <=2 cm | 490 (70.3%) | 489 (71.1%) | 492 (70.6%) | 486 (71.3%) | ||
| >2 cm | 194 (27.8%) | 182 (26.5%) | 188 (27.0%) | 181 (26.5%) | ||
| Missing | 13 (1.9%) | 17 (2.5%) | 17 (2.4%) | 15 (2.2%) | ||
| Cone biopsy | 0.652 | 0.993 | ||||
| Yes | 268 (38.5%) | 277 (40.3%) | 273 (39.1%) | 266 (39.1%) | ||
| No | 428 (61.4%) | 409 (59.4%) | 423 (60.7%) | 413 (60.7%) | ||
| Missing | 1 (0.1%) | 2 (0.3%) | 1 (0.2%) | 2 (0.2%) | ||
| Year of procedure | < 0.001 | 0.977 | ||||
| 2006–2008 | 127 (18.2%) | 57 (8.3%) | 93 (13.3%) | 86 (12.7%) | ||
| 2009–2011 | 254 (36.4%) | 160 (23.3%) | 210 (30.1%) | 203 (29.9%) | ||
| 2012–2014 | 184 (26.4%) | 253 (36.8%) | 220 (31.5%) | 217 (31.8%) | ||
| 2015–2017 | 132 (18.9%) | 218 (31.7%) | 174 (25.0%) | 175 (25.7%) | ||
| Adjuvant treatment | 0.028 | 0.409 | ||||
| Yes | 233 (33.4%) | 193 (28.1%) | 214 (30.7%) | 199 (29.2%) | ||
| No | 463 (66.4%) | 490 (71.2%) | 482 (69.1%) | 479 (70.3%) | ||
| Missing | 1 (0.1%) | 5 (0.7%) | 1 (0.1%) | 3 (0.5%) | ||
*The P-values were calculated by inverse probability of treatment-weighted logistic-regression models. Bold P-values are statistically significant.
†Counts in the weighted cohort may not sum to expected totals owing to rounding.